The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third FDA-approved indication. Perspective from David A. Eichenbaum, MD The FDA approved Susvimo ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab ...

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative ...

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) Safety data were ...

The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet age-related macular degeneration. The FDA approved Susvimo for the treatment of ...

Susvimo can help DR patients maintain their vision and prevent progression to blindness with only one treatment every nine months. Year to date, shares of Roche have risen 14.4% against the ...

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Approval of Susvimo marks the first continuous delivery therapy indicated for diabetic retinopathy. The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with ...

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab ...